Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
Daxor Corporation (DXR) has expanded its blood volume measurement technology to two new U.S. healthcare systems. The expansion includes: 1) Implementation of the ezBVA Lab service at a premier regional referral center in East Tennessee, providing comprehensive diagnostic results within 24 hours for outpatient cardiology services, and 2) Installation of an on-site BVA analyzer system at a leading healthcare facility in the Pacific Northwest for both inpatient and outpatient diagnostic needs.
The company's dual implementation model offers flexibility through both laboratory services and on-site systems. Daxor's proprietary technology provides gold-standard blood volume measurements that have been proven to reduce mortality, hospital readmissions, and length of stay in heart failure and critical care patients.
Daxor Corporation (DXR) ha ampliato la sua tecnologia di misurazione del volume sanguigno a due nuovi sistemi sanitari negli Stati Uniti. L'espansione comprende: 1) l'implementazione del servizio ezBVA Lab in un centro di riferimento regionale di primo livello nel East Tennessee, fornendo risultati diagnostici completi entro 24 ore per i servizi di cardiologia ambulatoriale, e 2) l'installazione di un sistema analizzatore BVA in loco presso una struttura sanitaria leader nel Pacific Northwest, per esigenze diagnostiche sia di pazienti ricoverati che ambulatoriali.
Il modello di implementazione duale dell'azienda offre flessibilità tramite servizi di laboratorio e sistemi in loco. La tecnologia proprietaria di Daxor fornisce misurazioni del volume sanguigno di standard oro, dimostrate efficaci nel ridurre mortalità, riammissioni ospedaliere e durata della degenza nei pazienti con insufficienza cardiaca e in cure critiche.
Daxor Corporation (DXR) ha ampliado su tecnología de medición del volumen sanguíneo a dos nuevos sistemas de salud en EE. UU. La expansión incluye: 1) la implementación del servicio ezBVA Lab en un centro regional de referencia de primer nivel en East Tennessee, proporcionando resultados diagnósticos completos en 24 horas para servicios ambulatorios de cardiología, y 2) la instalación de un sistema analizador BVA en sitio en una importante instalación sanitaria en el Pacific Northwest para necesidades diagnósticas tanto de pacientes hospitalizados como ambulatorios.
El modelo de implementación dual de la compañía ofrece flexibilidad a través de servicios de laboratorio y sistemas en sitio. La tecnología patentada de Daxor proporciona mediciones del volumen sanguíneo con estándar de oro, demostradas para reducir la mortalidad, las readmisiones hospitalarias y la duración de la estancia en pacientes con insuficiencia cardíaca y cuidados críticos.
Daxor Corporation (DXR)는 미국 내 두 개의 새로운 의료 시스템에 혈액량 측정 기술을 확장했습니다. 확장 내용은 다음과 같습니다: 1) East Tennessee의 주요 지역 진료 센터에 ezBVA Lab 서비스를 도입하여 외래 심장학 서비스에 대해 24시간 이내에 종합 진단 결과를 제공하고, 2) Pacific Northwest의 선도 의료 시설에 입원 환자 및 외래 환자 진단 요구를 위한 현장 BVA 분석기 시스템을 설치했습니다.
회사의 이중 구현 모델은 실험실 서비스와 현장 시스템을 통해 유연성을 제공합니다. Daxor의 독점 기술은 심부전 및 중환자 치료 환자에서 사망률, 병원 재입원 및 입원 기간을 줄이는 것으로 입증된 금본위 혈액량 측정을 제공합니다.
Daxor Corporation (DXR) a étendu sa technologie de mesure du volume sanguin à deux nouveaux systèmes de santé aux États-Unis. Cette expansion comprend : 1) la mise en place du service ezBVA Lab dans un centre régional de référence de premier plan à East Tennessee, offrant des résultats diagnostiques complets en 24 heures pour les services de cardiologie ambulatoire, et 2) l'installation d'un système d'analyse BVA sur site dans un établissement de santé majeur du Pacific Northwest pour répondre aux besoins diagnostiques des patients hospitalisés et ambulatoires.
Le modèle de double mise en œuvre de l'entreprise offre une flexibilité grâce aux services de laboratoire et aux systèmes sur site. La technologie propriétaire de Daxor fournit des mesures du volume sanguin de référence, prouvées pour réduire la mortalité, les réadmissions hospitalières et la durée de séjour chez les patients souffrant d'insuffisance cardiaque et en soins intensifs.
Daxor Corporation (DXR) hat seine Technologie zur Messung des Blutvolumens auf zwei neue Gesundheitssysteme in den USA ausgeweitet. Die Erweiterung umfasst: 1) die Implementierung des ezBVA Lab-Dienstes in einem führenden regionalen Überweisungszentrum in East Tennessee, das umfassende diagnostische Ergebnisse innerhalb von 24 Stunden für ambulante Kardiologiedienste liefert, und 2) die Installation eines vor Ort befindlichen BVA-Analysatorsystems in einer führenden Gesundheitseinrichtung im Pacific Northwest für diagnostische Bedürfnisse sowohl bei stationären als auch ambulanten Patienten.
Das duale Implementierungsmodell des Unternehmens bietet Flexibilität durch Laborservices und Vor-Ort-Systeme. Die proprietäre Technologie von Daxor liefert Blutvolumenmessungen nach Goldstandard, die nachweislich die Sterblichkeit, Wiederaufnahmen ins Krankenhaus und die Verweildauer bei Patienten mit Herzinsuffizienz und Intensivpflege reduzieren.
- Expansion into two new healthcare systems, increasing market presence
- Versatile implementation model offering both lab services and on-site systems
- Clinical proof of reducing mortality, hospital readmissions, and length of stay
- 24-hour turnaround time for diagnostic results
- None.
Insights
Daxor's expansion to two new healthcare systems shows growing market adoption of their blood volume diagnostic technology through flexible implementation models.
Daxor's announcement represents a strategic expansion of their blood volume analysis (BVA) technology into two additional U.S. healthcare markets through different deployment models. The company is implementing their diagnostic solution via their ezBVA Lab service at an East Tennessee referral center and an on-site BVA analyzer system at a Pacific Northwest healthcare facility.
This dual-model approach demonstrates Daxor's flexibility in meeting diverse clinical needs. The Tennessee implementation focuses on outpatient cardiology services with 24-hour turnaround via their CLIA-certified laboratory, while the Pacific Northwest installation supports both inpatient and outpatient diagnostics across cardiology and intensive care with immediate on-site analysis.
What's significant is how this expansion validates growing market recognition of BVA's clinical utility. Blood volume measurement represents a critical diagnostic parameter that has traditionally been difficult to assess accurately. Daxor's proprietary technology provides this measurement capability, which studies have shown can lead to reduced mortality, fewer hospital readmissions, and shorter lengths of stay in heart failure and critical care settings.
The company's ability to penetrate new healthcare systems suggests increasing market traction for their diagnostic solution, which addresses a substantial clinical need in cardiovascular and critical care medicine. Their flexible implementation strategy—offering both centralized lab services and on-site systems—allows them to adapt to different healthcare delivery models, potentially accelerating adoption.
Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation
Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide.
Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings. This strategic expansion includes:
- A premier regional referral center in East Tennessee has integrated Daxor's advanced ezBVA Lab service into its cardiology practice. Our CLIA-certified laboratory service, based in Tennessee, leverages state-of-the-art BVA technology-based analysis to deliver comprehensive diagnostic results within 24 hours, enhancing precision care for outpatient cardiology services.
- A leading comprehensive healthcare facility in the Pacific Northwest has implemented Daxor's on-site BVA analyzer system. This installation supports both inpatient and outpatient diagnostic needs across cardiology and intensive care departments, enabling immediate access to critical blood volume data that drives clinical decision-making.
“These implementations represent the versatility of Daxor's BVA solutions, which can be deployed through our concierge laboratory service and via on-site systems, ensuring healthcare providers have access to this vital diagnostic technology based upon their specific operational model,” said Michael Feldschuh, Daxor Corporation CEO. “Our continued expansion demonstrates the growing recognition that precise blood volume measurement is essential for optimizing patient outcomes in cardiovascular and critical care settings.”
The ezBVA Lab service and on-site BVA analyzers utilize Daxor's proprietary technology to deliver gold-standard blood volume measurements, empowering clinicians with actionable diagnostic insights that have been clinically proven to reduce mortality, hospital readmissions and length of stay when managing heart failure and other critical conditions.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 70,000 tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking projections are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What healthcare systems did Daxor (DXR) expand to in May 2025?
How does Daxor's (DXR) blood volume analysis technology improve patient outcomes?
What are the two implementation models offered by Daxor (DXR)?
How long does it take to get results from Daxor's (DXR) ezBVA Lab service?
